Show simple item record

dc.contributor.authorPastor Villaescusa, Belén
dc.contributor.authorPlaza Díaz, Julio
dc.contributor.authorEgea Zorrilla, Alejandro
dc.contributor.authorHoyos, Raúl
dc.contributor.authorGil Hernández, Ángel 
dc.contributor.authorAguilera García, Concepción María 
dc.date.accessioned2021-03-23T10:12:26Z
dc.date.available2021-03-23T10:12:26Z
dc.date.issued2020-12-24
dc.identifier.citationPastor-Villaescusa, B., Plaza-Díaz, J., Egea-Zorrilla, A., Leis, R., Bueno, G., Hoyos, R., ... & Aguilera, C. M. (2021). Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial. Biomedicine & Pharmacotherapy, 134, 111117. [https://doi.org/10.1016/j.biopha.2020.111117]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/67551
dc.description.abstractBackground: Metformin, a first-line oral antidiabetic agent that has shown promising results in terms of treating childhood and adolescent obesity, might influence the composition of the gut microbiota. We aimed to evaluate whether the gut microbiota of non-diabetic children with obesity changes after a metformin intervention. Methods: The study was a multicenter and double-blind randomized controlled trial in 160 children with obesity. Children were randomly assigned to receive either metformin (1 g/day) or placebo for 6 months in combination with healthy lifestyle recommendations in both groups. Then, we conducted a metagenomic analysis in a subsample obtained from 33 children (15 metformin, 18 placebo). A linear mixed-effects model (LMM) was used to determine the abundance changes from baseline to six months according to treatment. To analyze the data by clusters, a principal component analysis was performed to understand whether lifestyle habits have a different influence on the microbiota depending on the treatment group. Results: Actinobacteria abundance was higher after placebo treatment compared with metformin. However, the interaction time x treatment just showed a trend to be significant (4.6% to 8.1% after placebo vs. 3.8 % to 2.6 % after metformin treatment, p = 0.055). At genus level, only the abundance of Bacillus was significantly higher after the placebo intervention compared with metformin (2.5% to 5.7% after placebo vs. 1.5 % to 0.8 % after metformin treatment, p = 0.044). Furthermore, different ensembles formed by Firmicutes, Bacteroidetes, and Verrucomicrobia were found according to the interventions under a similar food consumptiones_ES
dc.description.sponsorshipSpanish Ministry of Health, Social and Equality, General Department for Pharmacy and Health Productses_ES
dc.description.sponsorshipInstituto de Salud Carlos III-Fondo de Investigación Sanitaria (FONDOS FEDER), Redes temáticas de investigación cooperativa RETIC Red SAMID RD12/0026/0015es_ES
dc.language.isoenges_ES
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevieres_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectMetformines_ES
dc.subjectMicrobiotaes_ES
dc.subjectChildren populationes_ES
dc.subjectPubertal stagees_ES
dc.subjectObesity es_ES
dc.titleEvaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.biopha.2020.111117
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España